Conference call today at 9:00 am ETQ4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs.
Conference call today at 8:30 a.m. ET ORLANDO, FLORIDA / ACCESS Newswire / March 9, 2026 / Unusual Machines (NYSE ...
Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the three months and full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results